In the study, Abbott’s FreeStyle Libre 2 system provided significant reduction in glycated hemoglobin. Credit: Abbott.

Abbott has reported positive data from a randomised clinical trial of its FreeStyle Libre 2 glucose monitoring system.

Published in The New England Journal of Medicine, the study evaluated the efficacy of the FreeStyle Libre 2 system in adult patients with Type 1 diabetes and sub-optimal glycaemic control.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The findings from the study demonstrated that Abbott’s glucose monitoring system provided a significant reduction in glycated hemoglobin (HbA1c) compared to self-monitoring of blood glucose (SMBG).

In the clinical trial, the participants sustained HbA1c reductions for the duration of the 24 week study.

Additionally, the FreeStyle Libre 2 system improved participant-reported quality of life outcomes, including overall satisfaction and reduction in burden related to glucose monitoring.

See Also:

The average HbA1c levels of participants who used the FreeStyle Libre 2 system were 0.8% less after six months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Abbott Diabetes Care Business chief medical officer Dr Mahmood Kazemi said: “This randomised study clearly illustrates the importance of continuous glucose monitoring for adults with Type 1 diabetes.

“This clinically-significant change in HbA1c levels shows FreeStyle Libre technology empowers people to make lifestyle decisions that improve their glucose control and, ultimately, may result in a reduction in diabetes-related health problems down the line.”

The study enrolled 156 people aged 16 years and above with Type 1 diabetes that were not previously familiar with continuous glucose sensing technology.

It was conducted as part of FLASH-UK, the first randomised study of the FreeStyle Libre 2 system in comparison to SMBG.

The clinical trial was funded by Diabetes UK and conducted by a team at The University of Manchester with support from investigators at eight centres around the UK.